Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cognitive outcome measures.

S H Ferris1

  • 1Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York 10016, USA.

Alzheimer Disease and Associated Disorders
|December 28, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Positron emission tomography in the study of aging and senile dementia.

Neurobiology of aging·2013
Same author

Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study.

International journal of clinical practice·2013
Same author

Novel white matter tract integrity metrics sensitive to Alzheimer disease progression.

AJNR. American journal of neuroradiology·2013
Same author

Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

The journal of nutrition, health & aging·2009
Same author

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.

The journal of nutrition, health & aging·2009
Same author

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.

Neurology·2009
Same journal

More Publications Needed on Cognitively Impaired-Not MCI: Call for Papers.

Alzheimer disease and associated disorders·2026
Same journal

CHMP2B p.Ala30Ser Variant in Biomarker-Confirmed Early-Onset Alzheimer Disease: A Potential Endolysosomal Disease Modifier.

Alzheimer disease and associated disorders·2026
Same journal

Early Gut Microbiome Alterations in Mild Cognitive Impairment Reflect Changes in Alzheimer Disease.

Alzheimer disease and associated disorders·2026
Same journal

Improvements in Cogstate Test Performance Depend on Number and Frequency of Prior Tests: Evidence from a Randomized Follow-Up Design.

Alzheimer disease and associated disorders·2026
Same journal

Identification of Functional lncRNAs in Alzheimer Disease by Integrative Analysis of lncRNA-mRNA Network Based on Competing Endogenous RNA Mechanism.

Alzheimer disease and associated disorders·2026
Same journal

Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical Trial.

Alzheimer disease and associated disorders·2026
See all related articles

Clinical trials for antidementia drugs require performance-based cognitive assessments. For vascular dementia trials, adapting Alzheimer

Area of Science:

  • Neurology
  • Clinical Trials
  • Cognitive Science

Background:

  • Antidementia drug trials necessitate validated performance-based cognitive assessments as primary outcomes.
  • Established criteria exist for selecting cognitive batteries in Alzheimer disease (AD) trials.
  • These criteria are also applicable to vascular dementia (VaD) trials.

Purpose of the Study:

  • To outline the essential criteria for developing an optimal cognitive assessment battery for vascular dementia (VaD) clinical trials.
  • To propose an efficient strategy for VaD battery development by leveraging existing Alzheimer disease (AD) instruments.

Main Methods:

  • Review and adaptation of established criteria for Alzheimer disease (AD) cognitive assessment batteries.
  • Identification of cognitive domains more prominently impaired in vascular dementia (VaD) compared to AD.

Related Experiment Videos

  • Proposal for augmenting a core AD cognitive battery with specific subtests for VaD.

    • Main Results:

    • The cognitive assessment strategy for VaD trials should mirror that of AD trials, emphasizing performance-based measures.
    • Significant overlap exists in cognitive impairment patterns between AD and VaD.
    • An efficient VaD battery can be developed by modifying a validated AD cognitive instrument.

    Conclusions:

    • Performance-based cognitive assessments are crucial for antidementia drug trials, including those for VaD.
    • Leveraging AD trial methodologies and instruments offers an efficient pathway for VaD battery development.
    • Tailoring existing AD batteries with VaD-specific subtests ensures comprehensive cognitive evaluation.